Peripheral T-Cell Lymphoma, Not Otherwise Specified

Peripheral T-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 72
Recruiting: 44
Ph III recruiting: 7
Growth YoY: —
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 29.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (41)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06671717	Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma	not yet recruiting	N/A	25	Peking University People's HospitalOTHER	1	Nov 6, 2024	clinicaltrials

Data updated 22 days agoSource updated Nov 6, 2024source: clinicaltrials